Summary The influence of the prototype aromatase inhibitor Aminoglutethimide (AG) and its analogue Rogletimide (RG) on peripheral aromatisation were investigated in 13 postmenopausal women with advanced breast cancer. Seven patients received AG 1,000 mg daily plus Hydrocortisone (HC) cover and six received.RG as dose escalation of 200 mg bd, 400 mg bd and 800 mg bd. In vivo aromatase inhibition was investigated using the double bolus injection technique with [4-14C] oestrone ([4-4C]E1) and [6,7-3H] androstenedione ([6,7-3H] 4A) followed by a 96 h urine collection. The labelled urinary oestrogens were separated and purified by chromatography and HPLC. Plasma oestradiol (E2) was also measured.
Hormonal manipulation is an effective treatment modality in 30% of post-menopausal women with advanced breast cancer (Stoll, 1981) . The majority of endocrine treatments for metastatic breast cancer are aimed at oestrogen deprivation of the cancer cell, either by oestrogen receptor blockade as with tamoxifen or by inhibition of peripheral oestrogen production by the aromatase system of enzymes. Peripheral aromatisation is the main source of post-menopausal oestrogens (Grodin et al., 1973) . Its inhibition was first shown to be an effective clinical treatment by (Hall et al., 1969) using Aminoglutethimide (AG) and since by many others (Santen et al., 1981; Harris et al., 1982) . AG is still the only widely available and used aromatase inhibitor. However at doses greater than 500 mg a day its inhibition of cholesterol side chain cleavage in the early steps of steroidogenesis and the partial blockade of in the adrenal necessitates its administration in conjunction with hydrocortisone to avoid hypoaldosteronism (Lonning & Kvinnsland, 1988) . AG has other side effects ranging from self limiting rashes to serious bone marrow suppression. Neuro-toxicity can be a particular problem in the elderly, limiting its use in a group of patients ideally suited to aromatase inhibition for palliating advanced disease. These problems have encouraged the development of new, more specific second generation aromatase inhibitors (Goss et al., 1986; Harris et al., 1988; Stein et al., 1990a Stein et al., , 1990b Dowsett et al., 1990) .
Rogletimide (RG) is a non-steroidal analogue of AG which during early development showed similar in vitro aromatase potency (Foster et al., 1985) . In vivo animal studies revealed a lack of toxic metabolites and CNS effects and volunteer/patient studies confirmed its ability to suppress E2 . RG did not inhibit cortisol production either by interaction with cholesterol side chain cleavage or with the 21-and 11P-hydroxylases and therefore does not require cortisone replacement . Pharmacokinetic data showed that RG induced its own hepatic metabolism similar to AG Aromatase suppression has been shown to be a more reliable and accurate indicator of inhibition of oestrogen synthesis than measuring the suppression of plasma E2 levels alone Patients, materials and methods
Patients
The protocol was approved by the hospital ethical committee and all patients gave informed consent. ARSAC clearance was obtained for the use of radio-isotopes in patients. Thirteen women with advanced metastatic cancer of the breast, suitable for second line endocrine therapy, were enrolled. All were post-menopausal: ten spontaneous (more than 5 years previously) two surgical and one radiotherapy ovarian ablation (all > 4 years previously). No systemic anticancer treatment had been given within the 4 weeks prior to the first aromatase study.
Demographic data are given in Table I .
Drugs
Arninoglutethimide Administered as 500 mg daily: 250 mg morning and evening for a fortnight then escalated to 1,000 mg daily: 250 mgs qds. Hydrocortisone cover was employed through out, 20 mg in the morning and 10 mg at night. No serious side effects were seen, three patients complained of mild lethargy and one a characteristic but self limiting rash. Rogletimide All patients started at 200 mg bd, escalated to 400 mg bd, and finally 800 mg bd. A minimum of 4 weeks was spent at each dose increment to ensure time for maximal liver enzyme induction and steady state drug levels to occur. At the end of the study patients were maintained on 400 mg bd provided there was no evidence of disease progression. Patient KD could not tolerate 800 mg bd because of malaise and lethargy, patient EH had difficulty in escalating to 800 mg bd because of severe headaches and malaise. This appeared to settle with time.
Study protocol Following previously published work Lonning et al., 1991) a double tracer bolus injection of 10 yiCi [4-'4C] El and 500 ftCi [6,7-3H] 4A dissolved in 54 ml of ethanol/saline (92:8 w/w) was administered i.v. before initiation of therapy (pre-treatment) and after a minimum of 4 weeks treatment at 250 mg qds for AG and at each dose increment for RG. In the case of RG this necessitated three on-treatment studies, at monthly intervals to investigate the effect of dose escalation. Prior to the injection of isotope blood samples were taken for endocrine analysis, the plasma separated by centrifugation and stored at -20°C. which is described below in brief. An 800 ml aliquot of urine was thawed and the steroids concentrated on Sep-Pak C18 cartridges. Chromatography on a DEAE 25 Sephadex column isolated the glucuronides using a salt gradient followed by further concentration and elimination of the salt on Sep-Pak C18 cartridges.
The glucuronides were incubated and hydrolysed for 48 h with 1 ml (144,000 units) of b glucuronidase. Following ether extraction the unconjugated oestrogens were separated from the androgens by three step column chromatography using DEAE 25 Sephadex. The final solution of the pure oestrogens, oestrone (El), oestradiol (E2) and Oestriol (E3) took place on a reverse phase HPLC using a Hypersil ODS 5 la (Chrompack) 4.6 x 250 mm column with an acetonitrile/ phosphate buffer 0.05 M pH 3 mobile phase.
Liquid scintillation counting A Packard tricarb 1990CA liquid scintillation beta counter with automatic Quench calibration was used to count 3H and 14C oestrogen and androgen peaks in all samples. Sample aliquots were counted in 10 ml plastic vials with Emulsifier Gold XR scintillation fluid (Packard) and expressed as D.P.M. The counting programme was optimised to eliminate channel crossover, which was 0.2%-0.4% for 3H in the 14C channel. There was no 14C to 3H cross over.
Endocrine assay Serum levels of E2, were measured according to previously described methodology (Dowsett et al., 1987 inhibition: rising from 50.6% ± 9.8 s.e.m. at 200 mg bd to a maximal suppression of 73.8% ± s.e.m. at 800 mg bd. Statistical significance was achieved (P-value <0.025 Friedman) but it was not possible to demonstrate any further significance between doses because of limited numbers of observations. Patient RB had the highest aromatase inhibition (90%) on treatment with RG. This was seen at 200 mg bd of RG with slight variations at 400 mg bd (75.6%) and 800 mg bd (86%). Patient EH exhibited a higher inhibition rate at 400 mg bd than 800 mg bd, the reason for this is unclear. RG aromatase inhibition rates showed wide interpatient variation at 200 mg bd (14.7-89.9%) and 400 mg bd (47.7-75.7%). Only at the 800 mg bd dose did the range fall (71.1-86.6%) corresponding to the narrower range seen with AG (84.6-97.8%). There was no correlation in the degree of aromatase inhibition to the magnitude of the pretreatment aromatase value for either RG or AG. AG caused significantly better aromatase inhibition than RG 800 mg bd (P <0.01 Wilcoxon).
On treatment with both AG and RG there was a consistent increase in the [4-14C] E3:Ej ratios for each individual (Table VI) . Figure 3 shows the individual patient ratio increases on a log scale (used for clarity as many of the data points were superimposed In',. ciminating between different drug schedule influences on oestrogen suppression . The isotopic tracer studies showed a maximal aromatase inhibition of 91% for AG 1,000 mg daily. This value is lower than the 98% previously reported (Santen et al., 1978) but used different methodology which may allow more accurate quantification of aromatase conversion rates and 4-hydroxyandrostenedione (4-OHA) 500 mg intramuscularly fortnightly , confirming the usefulness of AG for treating postmenopausal breast cancer.
It has yet to be demonstrated that the degree of aromatase inhibition correlates with clinical efficacy and it will be of interest to discover whether 4-OHA and CGS 16949A can match the clinical successes of AG. In comparison RG 800 mg bd achieved only 74% aromt atase inhibition. This further suggests that the difference in plasma E2 suppression between AG and RG reflects a true difference in pharmacological activity. RG shows a wide variation in the degree of aromatase inhibition at the lower patient selection, or previous treatments, as all demographic parameters were similar. The pre-treatment aromatase values and plasma E2 levels for all patients fell within previously described ranges (Santen et al., 1978; Jacobs et al., 1992) . The percentage E2 suppression for RG is consistent with previous work Haynes et al., 1991) . The difference in E2 suppression between the two drugs did not achieve statistical significance. This may be the result of small patient numbers or assay limited sensitivity making individual values uncertain. Aromatase inhibitors suppress the already low postmenopausal plasma E2 levels close to assay sensitivity limits which may be relevant in concealing further suppression. The lowest E2 levels seen for AG (2.8 pmol 1-') are at the limit of assay sensitivity. Those for RG (5.0 pmol 1') were not. This supports the difference between RG and AG in E2 suppression as being real. The degree of E2 suppression by RG is comparable to that seen with the other aromatase inhibitors currently under investigation (Dowsett et al., 1989 (Dowsett et al., , 1990 . However unpublished data from a previous study suggested that even at 800 mg bd, plasma RG trough levels were consistently below the required therapeutic threshold in 55% of patients. This contradiction may be the result of RG inducing its own metabolism similar to AG, induction only being detectable on more prolonged dosing schedules than previously studied i.e. 2 weeks compared with previous 5 days.
(ii) In the early stages of RG development it was chosen from a series of analogues (Leung et al., 1987) During this study it was noted that the E3:El isotope ratios in the urine changed in the on treatment situation for both AG and RG. This had not been noted in our previous in-vivo work on CGS 16949A and 4-OHA . Recent work has suggested that AG may have a dual mechanism of action in oestrogen suppression: (i) direct aromatase inhibition, (ii) stimulation of oestrogen metabolism consequent upon hepatic microsomal enzyme induction, increasing plasma ElS clearance and decreasing the ElS/El and ElS/E2 ratios (Lonning et al., 1987 (Lonning et al., , 1989b . The mechanism by which this occurs is stimulation of the 16 a hydroxylase enzyme (Lonning & Skulstad, 1989) which converts oestrogens to E3. Any alteration in the direction of oestrogen metabolism i.e. an increase towards E3 production and urinary excretion with a fall in that of El (Lonning et al., 1987) will be reflected in the change of oestrogen ratios. The change in oestrogen ratios is unlikely to be an analytical artifact: (i) we have not seen this phenomenon with any other aromatase inhibitors studied in this manner. (ii) El and E3 losses are probably similar through out the purification and separation stages of our analysis as both steroids unlike the catechol (2-OH) oestrogens are known to be chemically stable and do not undergo oxidative degradation. If a selective analytical loss of either of these oestrogens accounted for the ratio change it would be seen in all analysis not just those performed on RG and AG. If plasma ElS is quantitively a more important source of unconjugated oestrogens than androstendione in the postmenopausal women and a potential source of oestradiol in breast tumours (Santner et al., 1986) , reducing the circulating storage pool of ElS may give AG important clinical advantages over other more specific aromatase inhibitors (Lonning et al., 1989a) . As an AG analogue, RG would be expected to have similar properties. This hypothesis is indirectly supported by the comparable changes seen in the 14C E3:E1 isotope ratios on RG and AG treatment. 14C E3 :E1 ratio reversal similar to AG was seen at 800 mg bd of RG, indicating that comparable hepatic enzyme induction may be achieved at this dose of RG, even if aromatase inhibition is not. The wide interpatient variations in pre and on-treatment E3:E1 isotope ratios for both AG and RG is the result of unknown and known factors influencing hepatic enzyme function, e.g. diet, alcohol, drugs thyroid hormones. The differences seen between the 3H and 14C E3:E1 ratios in three patients in the on-treatment situation is difficult to explain. If, as the above results suggest, liver microsomal enzyme induction on RG is comparable to AG, then RG's suboptimal E2 suppression may be totally accounted for by inferior aromatase inhibition.
The difficulties of relying only on endocrine parameters for aromatase inhibitor assessment is underlined in the work presented here, for although the degree of E2 suppression for RG is lower than AG, which is consistent with its lower aromatase inhibition rates, it was not statistically significant. Until we can find or refute a link between oestrogen suppression and tumour response we can persue and investigate only those aromatase inhibitors deemed most 'effective pharmacologically by full aromatase evaluation.
Conclusion
At the maximum tolerated dose of 800 mg bd, RG achieves inferior E2 suppression and aromatase inhibition, compared with its parent compound AG. Whether this is the result of inadequate tissue/plasma drug concentration or poor aromatase inhibitory potency is of no clinical relevance as further dose escalation of RG is limited by toxicity. It is difficult to envisage a role for RG in the management of advanced breast cancer in view of newer, more pharmacologically effective aromatase inhibitors with minimal toxicity, now being developed. In vivo aromatisation measurements performed in conjunction with plasma oestrogen analysis creates a powerful tool for evaluating the optimal therapeutic dose and potential clinical efficacy of any new aromatase inhibitors in small groups of patients. Early evaluation employing these methods will select out aromatase inhibitors with low therapeutic potential reducing the need for multiple large scale clinical trials to assess clinical potential.
